Despite considerable progress in pharmacotherapy over the past seven decades, many
mental disorders remain insufficiently treated. This situation is in part due to the limited …

Background Accumulating evidence points to an association between gut microbial
abnormalities and depression disorder. The microbiota-gut-brain axis is an emerging target …

Depression disorder is rapidly advancing worldwide, and therapeutic strategy through gut–
brain axis has been proven to be effective in the treatment. Here we studied the effect of …

Discovery of innovative anxiolytics is severely hampering. Existing anxiolytics are developed
decades ago and are still the therapeutics of choice. Moreover, lack of new drug targets …

Increasing evidence points to the effect of the gut microbiota on central nervous system
functions. Supplementation of certain microbial strains has been demonstrated to alleviate …

Placebos are usually employed deceptively in clinical trials in order to control for non-
specific effects. However, since placebos themselves have been found to cause clinically …

Increasing research suggests a connection between gut microbiota and depressive
disorders. Targeted changes to the intestinal flora may contribute to alleviating anxiety and …

Objective: To evaluate the efficacy and long-term safety of vilazodone in children and
adolescent outpatients with major depressive disorder (MDD). Methods: Children and …

Abstract Serotonin (5-HT) acts as a morphogen influencing embryonic brain development,
and as a neurotransmitter regulating multiple biological functions with lifelong effects on …

This article provides an edited transcript of a moderated discussion between depression
experts Irving Kirsch and Michael Yapko regarding the role of antidepressants in the …